Leading into the ASH Annual Meeting, Dr. Kami Maddocks, professor in the Division of Hematology at The Ohio State University and medical director of infusion services at The James Comprehensive Cancer Center, provides an in-depth analysis of advancements in non-Hodgkin lymphoma care, with a focus on aggressive B-cell lymphoma. She explores the evolving roles of immunotherapies like CAR-T cells and bispecific antibodies in high-risk patient populations, discusses the impact of cell-of-origin testing on frontline treatment decisions, and evaluates the latest data guiding choices between R-CHOP, transplant, and CAR-T therapy after first relapse. Dr. Maddocks also highlights the promise of BTK inhibitors and maintenance approaches in transforming patient outcomes, offering insights into the future of lymphoma treatment.
Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/
Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA